Baseline patient and tumor characteristics
| Characteristic . | Enrolled (n = 54) . | Immunotherapy treated (n = 28) . |
|---|---|---|
| Median age, y (range) | 47 (21-60) | 49 (24-59) |
| Female, n (%) | 31 (57) | 18 (64) |
| Ethnicity, n (%) | ||
| White | 46 (85) | 25 (89) |
| Other | 8 (15) | 3 (11) |
| Cytogenetic risk group (%) | ||
| Poor | 20 | 11 |
| Intermediate | 65 | 75 |
| Normal | 50 | 54 |
| Other | 15 | 21 |
| Good | 15 | 14 |
| Leukemia cell harvest procedure, n (%) | ||
| Apheresis | 28 (52) | 15 (54) |
| Blood draw | 22 (41) | 11 (39) |
| Bone marrow aspiration | 4 (7) | 2 (7) |
| Leukemia cell immunophenotyping, % | ||
| CD13 | 91 | 91 |
| CD33 | 98 | 96 |
| CD34 | 75 | 68 |
| Blood stem cell collection, median CD34+ cells × 106/kg (range) | NA | 6.94 (0.34-14) |
| Primed lymphocyte collection, median CD3+ cells × 108/kg (range) | NA | 1.17 (0.67-96) |
| Characteristic . | Enrolled (n = 54) . | Immunotherapy treated (n = 28) . |
|---|---|---|
| Median age, y (range) | 47 (21-60) | 49 (24-59) |
| Female, n (%) | 31 (57) | 18 (64) |
| Ethnicity, n (%) | ||
| White | 46 (85) | 25 (89) |
| Other | 8 (15) | 3 (11) |
| Cytogenetic risk group (%) | ||
| Poor | 20 | 11 |
| Intermediate | 65 | 75 |
| Normal | 50 | 54 |
| Other | 15 | 21 |
| Good | 15 | 14 |
| Leukemia cell harvest procedure, n (%) | ||
| Apheresis | 28 (52) | 15 (54) |
| Blood draw | 22 (41) | 11 (39) |
| Bone marrow aspiration | 4 (7) | 2 (7) |
| Leukemia cell immunophenotyping, % | ||
| CD13 | 91 | 91 |
| CD33 | 98 | 96 |
| CD34 | 75 | 68 |
| Blood stem cell collection, median CD34+ cells × 106/kg (range) | NA | 6.94 (0.34-14) |
| Primed lymphocyte collection, median CD3+ cells × 108/kg (range) | NA | 1.17 (0.67-96) |